• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know?肾素-血管紧张素系统与严重急性呼吸综合征冠状病毒 2 感染的相关性:我们了解多少?
Eur J Pharmacol. 2020 Sep 15;883:173373. doi: 10.1016/j.ejphar.2020.173373. Epub 2020 Jul 15.
2
Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System: JACC Review Topic of the Week.SARS-CoV-2 与肾素血管紧张素系统相互作用的临床意义:美国心脏病学会评论专题周报。
J Am Coll Cardiol. 2020 Jun 23;75(24):3085-3095. doi: 10.1016/j.jacc.2020.04.028. Epub 2020 Apr 16.
3
Focus on clinical practice: angiotensin-converting enzyme 2 and corona virus disease 2019: pathophysiology and clinical implications.关注临床实践:血管紧张素转换酶 2 与 2019 年冠状病毒病:病理生理学与临床意义。
J Cardiovasc Med (Hagerstown). 2020 Sep;21(9):630-633. doi: 10.2459/JCM.0000000000001071.
4
Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2.新型冠状病毒肺炎疫情时期的心血管药理学:聚焦血管紧张素转换酶 2
J Cardiovasc Pharmacol. 2020 Jun;75(6):526-529. doi: 10.1097/FJC.0000000000000840.
5
Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic: Early Guidance and Evolving Evidence.2019冠状病毒病大流行期间肾素-血管紧张素系统阻滞剂的使用:早期指南及不断演变的证据
Can J Cardiol. 2020 Aug;36(8):1180-1182. doi: 10.1016/j.cjca.2020.05.033. Epub 2020 Jun 2.
6
Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury.新型冠状病毒相关肺损伤中经典肾素-血管紧张素系统与其拮抗系统之间的失衡。
Am J Physiol Lung Cell Mol Physiol. 2020 Aug 1;319(2):L325-L336. doi: 10.1152/ajplung.00189.2020. Epub 2020 Jul 8.
7
Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.新冠病毒病患者中的肾素-血管紧张素-醛固酮系统抑制剂
N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Epub 2020 Mar 30.
8
ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective.ACE2(血管紧张素转化酶 2)、COVID-19 以及大流行期间 ACE 抑制剂和血管紧张素 II(血管紧张素 II)受体阻滞剂的使用:儿科观点。
Hypertension. 2020 Jul;76(1):16-22. doi: 10.1161/HYPERTENSIONAHA.120.15291. Epub 2020 May 5.
9
Discovery and characterization of ACE2 - a 20-year journey of surprises from vasopeptidase to COVID-19.ACE2 的发现与特性鉴定——从血管紧张素转化酶到 2020 年冠状病毒病的 20 年探索之旅。
Clin Sci (Lond). 2020 Sep 30;134(18):2489-2501. doi: 10.1042/CS20200476.
10
Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients.停止使用 ACEI 和 ARB 类药物对 COVID-19 患者的潜在有害影响。
Elife. 2020 Apr 6;9:e57278. doi: 10.7554/eLife.57278.

引用本文的文献

1
Validity of mental and physical stress models.心理和生理压力模型的有效性。
Neurosci Biobehav Rev. 2024 Mar;158:105566. doi: 10.1016/j.neubiorev.2024.105566. Epub 2024 Feb 1.
2
Persistent Endothelial Lung Damage and Impaired Diffusion Capacity in Long COVID.长期新冠患者的持续性肺内皮损伤与弥散功能受损
J Pers Med. 2023 Aug 31;13(9):1351. doi: 10.3390/jpm13091351.
3
Altered microRNA Transcriptome in Cultured Human Airway Cells upon Infection with SARS-CoV-2.感染 SARS-CoV-2 后培养的人呼吸道细胞中微小 RNA 转录组的改变。
Viruses. 2023 Feb 10;15(2):496. doi: 10.3390/v15020496.
4
Effects of Vitamin D on the Renin-Angiotensin System and Acute Childhood Pneumonia.维生素D对肾素-血管紧张素系统及儿童急性肺炎的影响
Antibiotics (Basel). 2022 Nov 3;11(11):1545. doi: 10.3390/antibiotics11111545.
5
Overview of pharmacotherapy targeting COVID-19 disease based on ACE-2: current challenges and future directions.基于 ACE-2 的 COVID-19 疾病药物治疗概述:当前的挑战和未来的方向。
Herz. 2023 Oct;48(5):372-375. doi: 10.1007/s00059-022-05142-6. Epub 2022 Nov 4.
6
Pharmacotherapy Based on ACE2 Targeting and COVID-19 Infection.基于 ACE2 靶向和 COVID-19 感染的药物治疗。
Int J Mol Sci. 2022 Jun 14;23(12):6644. doi: 10.3390/ijms23126644.
7
Renin Angiotensin System and COVID-19 Infection.肾素-血管紧张素系统与新型冠状病毒肺炎感染
Adv Pharm Bull. 2022 Jan;12(1):1-4. doi: 10.34172/apb.2022.001. Epub 2021 Jan 23.
8
Modified mRNA-Based Vaccines Against Coronavirus Disease 2019.基于修饰信使 RNA 的 2019 年冠状病毒病疫苗。
Cell Transplant. 2022 Jan-Dec;31:9636897221090259. doi: 10.1177/09636897221090259.
9
Physiopathology and prospectives for therapeutic treatment of pulmonary fibrotic state in COVID-19 patients.COVID-19患者肺纤维化状态的病理生理学及治疗前景
Curr Res Pharmacol Drug Discov. 2021;2:100056. doi: 10.1016/j.crphar.2021.100056. Epub 2021 Sep 16.
10
Perspectives of association Baricitinib/Remdesivir for adults with Covid-19 infection.巴瑞替尼/瑞德西韦治疗成人 COVID-19 感染的关联观点。
Mol Biol Rep. 2022 Jan;49(1):827-831. doi: 10.1007/s11033-021-06888-8. Epub 2021 Nov 27.

本文引用的文献

1
Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.肾素-血管紧张素-醛固酮系统阻滞剂与新冠病毒风险。
N Engl J Med. 2020 Jun 18;382(25):2431-2440. doi: 10.1056/NEJMoa2006923. Epub 2020 May 1.
2
Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19.评估 COVID-19 发病机制中肺组织 ACE2 表达模式。
J Autoimmun. 2020 Aug;112:102463. doi: 10.1016/j.jaut.2020.102463. Epub 2020 Apr 13.
3
Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19.高血压、肾素-血管紧张素系统与下呼吸道感染和肺损伤风险:对 COVID-19 的影响。
Cardiovasc Res. 2020 Aug 1;116(10):1688-1699. doi: 10.1093/cvr/cvaa097.
4
Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers.2019冠状病毒病(COVID-19)感染与肾素-血管紧张素系统阻滞剂
JAMA Cardiol. 2020 Jul 1;5(7):745-747. doi: 10.1001/jamacardio.2020.1282.
5
Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.新冠病毒病患者中的肾素-血管紧张素-醛固酮系统抑制剂
N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Epub 2020 Mar 30.
6
SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?严重急性呼吸综合征冠状病毒2:2019冠状病毒病患者是否应停用肾素-血管紧张素系统抑制剂?
Eur Heart J. 2020 May 14;41(19):1801-1803. doi: 10.1093/eurheartj/ehaa235.
7
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?高血压和糖尿病患者感染新型冠状病毒肺炎(COVID-19)的风险会增加吗?
Lancet Respir Med. 2020 Apr;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8. Epub 2020 Mar 11.
8
COVID-19 and the cardiovascular system.新型冠状病毒肺炎与心血管系统。
Nat Rev Cardiol. 2020 May;17(5):259-260. doi: 10.1038/s41569-020-0360-5.
9
Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics.血管紧张素受体阻滞剂可作为治疗 SARS-CoV-2 的候选药物。
Drug Dev Res. 2020 Aug;81(5):537-540. doi: 10.1002/ddr.21656. Epub 2020 Mar 4.
10
Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target.血管紧张素转换酶2(ACE2)作为严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的受体:分子机制与潜在治疗靶点
Intensive Care Med. 2020 Apr;46(4):586-590. doi: 10.1007/s00134-020-05985-9. Epub 2020 Mar 3.

肾素-血管紧张素系统与严重急性呼吸综合征冠状病毒 2 感染的相关性:我们了解多少?

Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know?

机构信息

Usl Umbria 1, Perugia, Italy.

Usl Umbria 1, Perugia, Italy.

出版信息

Eur J Pharmacol. 2020 Sep 15;883:173373. doi: 10.1016/j.ejphar.2020.173373. Epub 2020 Jul 15.

DOI:10.1016/j.ejphar.2020.173373
PMID:32679185
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7361104/
Abstract

The first cases of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2 or COVID-19) infections were recorded in China in November 2019. Since its appearance in China at the end of last year, the virus has spread to all continents causing a "global pandemic". To date, some aspects remain to be investigate about the pathophysiology of this viral infection. One of the aspects to be still clarified is the correlation between the renin-angiotensin system (RAS) and SARS-CoV-2 infection. RAS is a physiological system playing a key role in different human body functions regulation. SARS-CoV-2 uses the angiotensin-converting enzyme 2 (ACE-2), a component of RAS, as a potential factor of cell penetration and infectivity; in addition, in the different infection stages, a functional variation of the RAS has been noted. In this article, we discuss the correlation between the role of RAS and system-modifying agents, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs) and direct renin inhibitors (DRIs), with SARS-CoV-2 infection.

摘要

严重急性呼吸综合征冠状病毒 2(SARS-CoV-2 或 COVID-19)感染的首例病例于 2019 年 11 月在中国记录。自去年年底在中国出现以来,该病毒已传播到所有大陆,造成“全球大流行”。迄今为止,关于这种病毒感染的病理生理学仍有一些方面需要研究。其中一个需要澄清的方面是肾素-血管紧张素系统(RAS)与 SARS-CoV-2 感染之间的相关性。RAS 是一个在调节人体不同功能方面发挥关键作用的生理系统。SARS-CoV-2 使用血管紧张素转换酶 2(ACE-2),即 RAS 的一个组成部分,作为细胞穿透和传染性的潜在因素;此外,在不同的感染阶段,RAS 的功能发生了变化。在本文中,我们讨论了 RAS 及其系统修饰剂(血管紧张素转换酶抑制剂[ACEI]、血管紧张素 II 受体阻滞剂[ARB]和直接肾素抑制剂[DRI])与 SARS-CoV-2 感染之间的相关性。